Marburg Virus Disease Clinical Trials and Pipeline Analysis 2024: FDA, EMA and PDMA Approvals, Therapies, and Key Companies by DelveInsight | BioCryst Pharmaceuticals, Bavarian Nordic, Flow Pharma, Pu

February 28
04:48 2024
Marburg Virus Disease Clinical Trials and Pipeline Analysis 2024: FDA, EMA and PDMA Approvals, Therapies, and Key Companies by DelveInsight | BioCryst Pharmaceuticals, Bavarian Nordic, Flow Pharma, Pu
Marburg Virus Disease Pipeline

DelveInsight’s, “Marburg Virus Disease Pipeline Insight, 2024” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Marburg Virus Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

To know more about the Marburg Virus Pipeline report offerings, click here @ Marburg Virus Disease Pipeline Analysis

 

Some facts of the Marburg virus Pipeline report are:

  • Leading Marburg Virus companies such as Amicus Therapeutics Inc., Alexion Pharmaceuticals Inc., BioCryst Pharmaceuticals, Bavarian Nordic, Bio-Rad Laboratories Inc., AlphaVax, GW Pharmaceuticals Plc, Takeda Pharmaceutical Company Limited, Mapp Biopharmaceutical, Collaborations Pharmaceuticals Inc., Emergent BioSolutions Inc., BioMarin and Sarepta Therapeutics, Alkido Pharma, Biofactura, and others are developing potential drug candidates to improve the Marburg Virus Disease treatment scenario.
  • Galidesivir (BCX4430) is a broad-spectrum antiviral in advanced development for the virus treatment. BioCryst is developing galidesivir in partnership with U.S. government agencies and other institutions. In September 2013, NIAID contracted with BioCryst to develop galidesivir to treat Marburg Virus Disease and potentially for other filoviruses, including the Ebola virus. The drug is currently in phase 1 of clinical trials for the treatment of Marburg Virus Disease.
  • BioCryst is developing galidesivir in partnership with U.S. government agencies and other institutions. In September 2013, the National Institute of Allergy and Infectious Diseases (NIAID) contracted with BioCryst to develop galidesivir to treat Marburg virus disease and potentially for other filoviruses, including the Ebola virus.
  • Integrated BioTherapeutics Inc. (IBT), in May 2021, announced the receipt of a contract valued at up to USD 16.3 million from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to develop IBT-T03H, a monoclonal antibody for the treatment of Marburg virus disease (MVD).
  • Mapp Biopharmaceutical, Inc. has been given an advanced research and development contract for USD 16.5 million with options for an additional USD 30.0 million by the Biomedical Advanced Research and Development Authority (BARDA) at the U.S. Department of Health and Human Services (HHS) to advance MBP091 through the completion of Phase 1 clinical trial. MBP091 is a single human monoclonal antibody (mAb) developed as a pan-Marburg virus therapeutic for the treatment of hemorrhagic fevers that are caused by Marburg and the closely related Ravn virus.

 

Marburg virus Overview: Marburg virus was first recognized in 1967, when outbreaks of hemorrhagic fever occurred simultaneously in laboratories in Marburg and Frankfurt, Germany and in Belgrade, Yugoslavia (now Serbia). Marburg hemorrhagic fever (Marburg HF) is a rare but severe hemorrhagic fever which affects both humans and non-human primates. Marburg HF is caused by Marburg virus, a genetically unique zoonotic (or, animal-borne) RNA virus of the filovirus family.

 

Some of the Marburg Virus Disease Companies are:

  • BioCryst Pharmaceuticals
  • Amicus Therapeutics Inc.
  • Alexion Pharmaceuticals Inc.
  • BioCryst Pharmaceuticals
  • Bavarian Nordic
  • Bio-Rad Laboratories, Inc.
  • AlphaVax
  • GW Pharmaceuticals Plc
  • Takeda Pharmaceutical Company Limited
  • Mapp Biopharmaceutical
  • Collaborations Pharmaceuticals Inc.
  • Emergent BioSolutions Inc.
  • BioMarin and Sarepta Therapeutics
  • Alkido Pharma
  • Biofactura
  • And Others

 

Request for free Sample Report to know in detail about the Marburg Virus Disease clinical trials landscape: https://www.delveinsight.com/sample-request/marburg-virus-disease-pipeline-insight

 

DelveInsight’s Marburg Virus Disease report covers around 6+ products under different phases of clinical development like

  • Late-stage products (Phase III and
  • Mid-stage products (Phase II and
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Some of the Marburg Virus Disease Therapies are:

  • MVA-BN filovirus vaccine
  • Galidesivir
  • And Many Others

 

Request for free Sample Report to know in detail about Marburg Virus Disease treatment landscape: https://www.delveinsight.com/sample-request/marburg-virus-disease-pipeline-insight

 

Current  Marburg Virus Disease Treatment Scenario and  Marburg Virus Disease Emerging Therapies:

  • How many companies are developing Marburg Virus Disease drugs?
  • How many Marburg Virus Disease drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for Marburg Virus Disease?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Marburg Virus Disease therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Marburg Virus Disease and their status?
  • What are the key designations that have been granted to the emerging drugs?

 

Request for free Sample Report to know more about epidemiology trends: https://www.delveinsight.com/sample-request/marburg-virus-disease-pipeline-insight

 

Table of Contents:

Introduction

Executive Summary

Marburg Virus Disease: Overview

Marburg Virus Disease Pipeline Therapeutics

  • Comparative Analysis

Marburg Virus Disease Therapeutic Assessment

Marburg Virus Disease – DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

Mid Stage Products (Phase II)

  • Comparative Analysis

MVA-BN filovirus vaccine: Bavarian Nordic

Drug profiles in the detailed report…..

Early Stage Products (Phase I)

  • Comparative Analysis

Galidesivir: BioCryst Pharmaceuticals

Drug profiles in the detailed report…..

Inactive Products

Marburg Virus Disease Companies

Marburg Virus Disease Key Products

Marburg Virus Disease Unmet Needs

Marburg Virus Disease Market Drivers

Marburg Virus Disease Market Barriers

Marburg Virus Disease- Future Perspectives and Conclusion

Marburg Virus Disease Analyst Views

Marburg Virus Disease Key Companies

Appendix

 

Request for Detailed TOC: https://www.delveinsight.com/sample-request/marburg-virus-disease-pipeline-insight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services

Categories